Beyond that, lack of specificity is assumed for diverse TKIs including erlotinib and gefitinib [39], suggesting putative further targets of strong homology such as ERBB2/HER2 which might be especially noticeable in the pool of p-SCC cells derived from a tumor with heterogeneous EGFR expression. The gene discussed is EGFR; the disease is neoplasm.